Intellia Therapeutics, Inc.

NasdaqGM:NTLA Stock Report

Market Cap: US$1.9b

Intellia Therapeutics Valuation

Is NTLA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of NTLA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: NTLA ($12.89) is trading below our estimate of future cash flow value ($161.36)

Significantly Below Future Cash Flow Value: NTLA is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NTLA?

Key metric: As NTLA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NTLA. This is calculated by dividing NTLA's market cap by their current revenue.
What is NTLA's PS Ratio?
PS Ratio27.3x
SalesUS$66.09m
Market CapUS$1.88b

Price to Sales Ratio vs Peers

How does NTLA's PS Ratio compare to its peers?

The above table shows the PS ratio for NTLA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average27.6x
RXRX Recursion Pharmaceuticals
25.7x31.30%US$1.8b
VCEL Vericel
6.5x14.79%US$1.8b
NRIX Nurix Therapeutics
22.5x33.56%US$1.6b
GENB Generate Biomedicines
55.8x33.49%US$1.6b
NTLA Intellia Therapeutics
27.3x55.65%US$1.9b

Price-To-Sales vs Peers: NTLA is good value based on its Price-To-Sales Ratio (27.3x) compared to the peer average (27.6x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does NTLA's PS Ratio compare vs other companies in the US Biotechs Industry?

125 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
3x2.51%US$28.44b
INCY Incyte
3.8x-1.52%US$20.11b
BMRN BioMarin Pharmaceutical
3.5x10.07%US$10.93b
ACAD ACADIA Pharmaceuticals
3.4x10.08%US$3.72b
NTLA 27.3xIndustry Avg. 10.4xNo. of Companies125PS01632486480+
125 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NTLA is expensive based on its Price-To-Sales Ratio (27.3x) compared to the US Biotechs industry average (10.4x).

Price to Sales Ratio vs Fair Ratio

What is NTLA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NTLA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio27.3x
Fair PS Ratio0.09x

Price-To-Sales vs Fair Ratio: NTLA is expensive based on its Price-To-Sales Ratio (27.3x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NTLA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$12.89
US$26.63
+106.61%
74.64%US$95.00US$8.00n/a19
Jun ’27US$13.73
US$26.63
+93.97%
74.64%US$95.00US$8.00n/a19
May ’27US$13.26
US$26.80
+102.11%
74.59%US$95.00US$5.00n/a20
Apr ’27US$13.27
US$25.29
+90.55%
84.23%US$106.00US$5.00n/a21
Mar ’27US$13.78
US$24.05
+74.51%
91.04%US$106.00US$5.00n/a21
Feb ’27US$13.15
US$23.86
+81.42%
92.36%US$106.00US$5.00n/a21
Jan ’27US$8.99
US$22.43
+149.52%
97.96%US$106.00US$4.00n/a22
Dec ’26US$8.42
US$22.43
+166.41%
97.96%US$106.00US$4.00n/a22
Nov ’26US$12.62
US$29.76
+135.82%
80.38%US$106.00US$8.00n/a23
Oct ’26US$18.76
US$34.64
+84.63%
71.64%US$106.00US$8.00n/a22
Sep ’26US$11.36
US$33.54
+195.36%
71.74%US$106.00US$7.00n/a26
Aug ’26US$11.49
US$36.04
+213.65%
67.50%US$106.00US$7.00n/a26
Jul ’26US$9.88
US$37.30
+277.49%
65.46%US$106.00US$7.00n/a27
Jun ’26US$6.87
US$39.19
+470.38%
63.25%US$106.00US$7.00US$13.7327
May ’26US$8.64
US$41.81
+383.97%
59.23%US$106.00US$8.00US$13.2627
Apr ’26US$6.66
US$43.92
+560.00%
55.53%US$106.00US$9.00US$13.2726
Mar ’26US$10.09
US$46.08
+356.69%
56.99%US$106.00US$9.00US$13.7825
Feb ’26US$10.32
US$50.80
+392.26%
52.32%US$106.00US$10.00US$13.1525
Jan ’26US$11.66
US$59.89
+413.60%
44.01%US$128.00US$14.00US$8.9926
Dec ’25US$15.62
US$59.78
+282.71%
43.27%US$128.00US$14.00US$8.4227
Nov ’25US$14.81
US$64.33
+334.40%
46.05%US$144.00US$14.00US$12.6227
Oct ’25US$19.20
US$67.48
+251.47%
40.89%US$144.00US$24.00US$18.7627
Sep ’25US$22.44
US$69.12
+208.01%
40.06%US$144.00US$24.00US$11.3626
Aug ’25US$25.14
US$70.26
+179.48%
38.08%US$144.00US$24.00US$11.4926
Jul ’25US$22.47
US$70.26
+212.69%
38.08%US$144.00US$24.00US$9.8826
Jun ’25US$21.38
US$70.26
+228.63%
38.08%US$144.00US$24.00US$6.8726
US$26.63
Fair Value
51.6% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 19:00
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Intellia Therapeutics, Inc. is covered by 35 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Brian SkorneyBaird
William PickeringBernstein